Vanessa King

Vanessa King is a highly accomplished professional with a diverse background in the biotechnology industry, spanning over several prestigious organizations.

She pursued her education at renowned institutions including Kent Place School, the University of Cambridge where she obtained a Ph.D. in Molecular Genetics, and Princeton University.

With a rich history of executive roles, Vanessa currently serves as the Chief Executive Officer at Tenpoint Therapeutics, showcasing her exceptional leadership skills and strategic acumen.

Prior to her current position, Vanessa held key roles such as President & CEO at Virion Biotherapeutics, Venture Partner at Abingworth, and Executive Chairman at TIAKI THERAPEUTICS, reflecting her versatility and expertise in the field.

Her career also includes vital positions such as Entrepreneur in Residence at Atlas Venture, President and CEO at Cadent Therapeutics, and Executive Director at Amgen, demonstrating her strong presence in various facets of the biotech sector.

Vanessa King's extensive experience ranges from Vice President roles at established companies like deCODE genetics and J. Craig Venter Institute, to steering committees and strategic operations at Novartis Pharmaceuticals, showcasing her comprehensive knowledge and proficiency across different domains within the industry.

She has also held strategic roles in business development and partnerships, evident from her positions at BioScale, Inc., PerkinElmer, and McKinsey & Company, underlining her expertise in driving growth and innovation through collaborative efforts.

Vanessa's contributions as a Board Member at AZAFAROS B.V. and her entrepreneurial endeavors at F-Prime Capital further exemplify her commitment to fostering advancements in biotechnology and healthcare.

In summary, Vanessa King emerges as a seasoned professional with a strong academic foundation, extensive leadership experience, and a demonstrated track record of success in the biotechnology landscape.